How to buy UroGen Pharma stock

UroGen Pharma Ltd is a biotechnology business based in the US. UroGen Pharma shares (URGN) are listed on the NASDAQ and all prices are listed in US Dollars. UroGen Pharma employs 187 staff and has a trailing 12-month revenue of around USD$3.8 million.

How to buy shares in UroGen Pharma

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for UroGen Pharma. Find the stock by name or ticker symbol: URGN. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until UroGen Pharma reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of UroGen Pharma, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of UroGen Pharma. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Our top pick for

Beginners

Robinhood

Our top pick for

Building a portfolio

Sofi Invest

Our top pick for

Advanced traders

Interactive Brokers

How we chose our top picks

We evaluate stock trading platforms against a range of metrics that include fees, ease of use, available securities and advanced tools to meet specific investor needs. We encourage you to compare stock platforms to find one that's best for your particular budget and goals.

• Our pick for beginners. We chose Robinhood for this category because it offers commission-free trading and is easy to use. You can search for stocks by company name, and the mobile app is clean and intuitive to use.
• Our pick for building a portfolio. We chose SoFi for this category because it offers both commission-free stocks and a free robo-advisor. That means you can open an active investing account to pick and choose companies you want to invest in, and open a robo-advisor account to help you build a portfolio and manage how much risk you take on.
• Our pick for active traders. We picked Interactive Brokers for this category because it offers advanced tools and low fees for active investors and pros. The simpler IBKR Lite platform is aimed at less-active investors, but all users older than 21 must meet a $20,000 liquid net worth requirement for a cash account.

What's in this guide?

1. URGN shares summary
2. Compare share dealing platforms
3. Is URGN stock a buy or sell?
4. Stock performance over time
5. Can I short URGN shares?
6. UroGen Pharma's financials
7. How volatile are URGN shares?
8. Does UroGen Pharma pay a dividend?
9. Other common questions

UroGen Pharma share price

Use our graph to track the performance of URGN stocks over time.

UroGen Pharma shares at a glance

• Key figures

Information last updated 2021-02-23.

52-week range	USD$13.1184 - USD$30.89
50-day moving average	USD$22.5396
200-day moving average	USD$21.5923
Wall St. target price	USD$41
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$-4.888

Buy UroGen Pharma shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Sort by:

Name	Product	Stock trade fee	Asset types	Option trade fee	Annual fee	Signup bonus
Robinhood		$0	Stocks, Options, ETFs, Gold/Commodities	$0	0%	Free stock (chosen randomly with a value anywhere between $2.50 and $200) Sign up using the "go to site" link	Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.	Go to site More Info		loading Fetching your data...
Interactive Brokers		$0	Stocks, Bonds, Options	$0 + $0.65/contract, $1 minimum	0%	N/A	IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.	Go to site More Info		loading Fetching your data...
Tastyworks		$0	Stocks, Options, Cryptocurrency	Stocks & ETFs: $1/contract to open, $0 to close, $10 max/leg Futures: $2.50/contract to open, $0 to close	0%	Get 100 shares of stock (worth $1 to $6 a share) Open and fund a new cash or margin account with $2,000+	Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.	Go to site More Info		loading Fetching your data...
Moomoo		$0 for US stocks	Stocks, Options, ETFs	$0		N/A	Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.	Go to site More Info		loading Fetching your data...
TradeStation		$0	Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency	$0 + $0.50/contract		$50 Deposit qualifying assets of $5,000+	A platform built for all kinds of traders and all styles of trading	Go to site More Info		loading Fetching your data...

loading

Compare up to 4 providers

Clear selection

Compare

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy UroGen Pharma stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of UroGen Pharma Ltd by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Shorting UroGen Pharma shares

There are currently 2.6 million UroGen Pharma shares held short by investors – that's known as UroGen Pharma's "short interest". This figure is 0.9% down from 2.6 million last month.

There are a few different ways that this level of interest in shorting UroGen Pharma shares can be evaluated.

UroGen Pharma's "short interest ratio" (SIR)

UroGen Pharma's "short interest ratio" (SIR) is the quantity of UroGen Pharma shares currently shorted divided by the average quantity of UroGen Pharma shares traded daily (recently around 202772.34701782). UroGen Pharma's SIR currently stands at 12.91. In other words for every 100,000 UroGen Pharma shares traded daily on the market, roughly 12910 shares are currently held short.

However UroGen Pharma's short interest can also be evaluated against the total number of UroGen Pharma shares, or, against the total number of tradable UroGen Pharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case UroGen Pharma's short interest could be expressed as 0.12% of the outstanding shares (for every 100,000 UroGen Pharma shares in existence, roughly 120 shares are currently held short) or 0.1471% of the tradable shares (for every 100,000 tradable UroGen Pharma shares, roughly 147 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against UroGen Pharma.

Find out more about how you can short UroGen Pharma stock.

UroGen Pharma share price volatility

Over the last 12 months, UroGen Pharma's shares have ranged in value from as little as $13.1184 up to $30.89. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while UroGen Pharma's is 1.2555. This would suggest that UroGen Pharma's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

UroGen Pharma overview

UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing solutions for specialty cancers and urologic diseases. The company's lead product candidates are UGN-101 and UGN-102, which are designed to ablate tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-201, a proprietary immunotherapy product candidate for the treatment of high-grade non-muscle invasive bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for high-grade bladder cancer. UroGen Pharma Ltd. was founded in 2004 and is based in Princeton, New Jersey.

Frequently asked questions

• What percentage of UroGen Pharma is owned by insiders or institutions?

  Currently 12.737% of UroGen Pharma shares are held by insiders and 75.179% by institutions.

• How many people work for UroGen Pharma?

  Latest data suggests 187 work at UroGen Pharma.

• When does the fiscal year end for UroGen Pharma?

  UroGen Pharma's fiscal year ends in December.

• Where is UroGen Pharma based?

  UroGen Pharma's address is: 400 Alexander Park, Princeton, NJ, United States, 08540

• What is UroGen Pharma's ISIN number?

  UroGen Pharma's international securities identification number is: IL0011407140

• What is UroGen Pharma's CUSIP number?

  UroGen Pharma's Committee on Uniform Securities Identification Procedures number is: M96088105